Novo Nordisk Inks Its Second Big Obesity Deal In A Week — And It's Not For A GLP-1
Novo Nordisk will pay Lexicon $1 billion up front to license its experimental obesity treatment. The news sent penny stock Lexicon flying. The post Novo Nordisk Inks Its Second Big Obesity Deal In A Week — And It's Not For A GLP-1 appeared first on Investor's Business Daily.
Novo Nordisk will pay Lexicon $1 billion up front to license its experimental obesity treatment. The news sent penny stock Lexicon flying.
The post Novo Nordisk Inks Its Second Big Obesity Deal In A Week — And It's Not For A GLP-1 appeared first on Investor's Business Daily.
iShook Opinion
"iShook Opinion" by Beni E Rachmanov, CEO & Founder of iShook. Explore captivating perspectives on entertainment, lifestyle, and sports at ishookdaily.com. Your go-to for engaging insights.
